Real-World Analysis of Durvalumab after Chemoradiation in Stage III Non-Small-Cell Lung Cancer

The 2017 PACIFIC trial heralded the incorporation of routine adjuvant durvalumab following curative-intent chemoradiation for stage III non-small-cell lung cancer (NSCLC). However, carefully selected clinical trial populations can differ significantly from real-world populations, which can have impl...

وصف كامل

التفاصيل البيبلوغرافية

المؤلفون الرئيسيون:	Beatrice T. B. Preti, Michael S. Sanatani, Daniel Breadner, Suganija Lakkunarajah, Carolyn Scott, Caroline Esmonde-White, Eric McArthur, George Rodrigues, Mitali Chaudhary, Adam Mutsaers, Robin Sachdeva, Mark D. Vincent
التنسيق:	Artigo
اللغة:	Inglês
منشور في:	MDPI AG 2023-08-01
سلاسل:	Current Oncology
الموضوعات:	durvalumab non-small-cell lung cancer stage III lung cancer immunotherapy pneumonitis
الوصول للمادة أونلاين:	https://www.mdpi.com/1718-7729/30/8/559
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!